КЛІНІЧНІ ДОКАЗИ ДОЦІЛЬНОСТІ ЗАСТОСУВАННЯ КОЛХІЦИНУ ПАЦІЄНТАМИ ІЗ АТЕРОСКЛЕРОТИЧНИМИ СЕРЦЕВО-СУДИННИМИ ЗАХВОРЮВАННЯМИ (ОГЛЯД ЛІТЕРАТУРИ)
DOI:
https://doi.org/10.24061/1727-4338.XXI.4.82.2022.11Ключові слова:
колхіцин, протизапальний препарат, атеросклероз, запалення, біомаркери, ішемічна хвороба серцяАнотація
Мета роботи – проаналізувати дані світової літератури стосовно механізмів впливу
протизапальної терапії колхіцином на прогноз пацієнтів з атеросклеротичними
серцево-судинними захворюваннями (АССЗ) з оцінкою результатів проведеного
пошуку.
Висновок. Сучасні дослідження показали, що колхіцин, як протизапальний препарат,
стає цінним, безпечним і економічно вигідним засобом у вторинній профілактиці АССЗ.
Посилання
Butt AK, Cave B, Maturana M, Towers WF, Khouzam RN.
The Role of Colchicine in Coronary Artery Disease. Curr Probl
Cardiol [Internet]. 2021[cited 2022 Nov 29];46(3):100690.
Available from: https://www.sciencedirect.com/science/article/
abs/pii/S0146280620301675?via%3Dihub doi: 10.1016/j.
cpcardiol.2020.100690
Lázaro AMP, Blanco- Colio LM, Peláez JAF, Tuñón J. AntiInflammatory Drugs in Patients with Ischemic Heart Disease. J Clin
Med [Internet]. 2021[cited 2022 Nov 27];10(13):2835. Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268779/
pdf/jcm-10-02835.pdf doi: 10.3390/jcm10132835
Ullah W, Haq S, Zahid S, Gowda SN, Ottman P, Saleem S, et al.
Safety and Efficacy of Colchicine in Patients with Stable CAD and
ACS: A Systematic Review and Meta-analysis. Am J Cardiovasc
Drugs. 2021;21(6):659-68. doi: 10.1007/s40256-021-00485-7
Biasucci LM, Pedicino D, Liuzzo G. Promises and challenges of
targeting inflammation to treat cardiovascular disease: the postCANTOS era. Eur Heart J. 2020;41(23):2164-7. doi: 10.1093/
eurheartj/ehz586
Ridker PM. From CANTOS to CIRT to COLCOT to Clinic: Will
All Atherosclerosis Patients Soon Be Treated With Combination Lipid- Lowering and Inflammation- Inhibiting Agents? Circulation.
;141(10):787-9. doi: 10.1161/circulationaha.119.045256
D’Amario D, Cappetta D, Cappannoli L, Princi G, Migliaro S,
Diana G, et al. Colchicine in ischemic heart disease: the good, the
bad and the ugly. Clin Res Cardiol. 2021;110(10):1531-42. doi:
1007/s00392-021-01828-9
Imazio M, Nidorf M. Colchicine and the heart. Eur Heart J.
;42(28):2745-60. doi: 10.1093/eurheartj/ehab221
Angelini F, Bocchino PP, Imazio M. Colchicine and coronary artery
disease: a virtuous adoption. Eur Heart J. 2021;42(28):2796-7. doi:
1093/eurheartj/ehab008
Arnold N, Lechner K, Waldeyer C, Shapiro MD, Koenig
W. Inflammation and Cardiovascular Disease: The Future. Eur
Cardiol [Internet]. 2021[cited 2022 Nov 29];16: e20. Available
from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157394/
pdf/ecr-16-e20.pdf doi: 10.15420/ecr.2020.50
Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily)
on high sensitivity c-reactive protein independent of aspirin and
atorvastatin in patients with stable coronary artery disease. Am J
Cardiol. 2007;99(6):805-7. doi: 10.1016/j.amjcard.2006.10.039
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Lowdose colchicine for secondary prevention of cardiovascular
disease. J Am Coll Cardiol. 2013;61(4):404-10. doi: 10.1016/j.
jacc.2012.10.027
Bouabdallaoui N, Tardif JC. Colchicine in the Management of
Acute and Chronic Coronary Artery Disease. Curr Cardiol Rep
[Internet]. 2021[cited 2022 Nov 30];23(9):120. Available from:
https://link.springer.com/article/10.1007/s11886-021-01560-w
doi: 10.1007/s11886-021-01560-w
Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal
TSJ, et al. Colchicine in patients with chronic coronary disease. N
Engl J Med. 2020;383(19):1838-47. doi: 10.1056/nejmoa2021372
Jia X, Al Rifai M, Hussain A, Martin S, Agarwala A, Virani
SS. Highlights from Studies in Cardiovascular Disease
Prevention Presented at the Digital 2020 European Society
of Cardiology Congress: Prevention Is Alive and Well. Curr
Atheroscler Rep [Internet]. 2020[cited 2022 Nov 27];22(12):72.
Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC7532123/pdf/11883_2020_Article_895.pdf doi: 10.1007/
s11883-020-00895-z
Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS,
Keech AC, et al. Efficacy and safety of low-dose colchicine in
patients with coronary disease: a systematic review and metaanalysis of randomized trials. Eur Heart J. 2021;42(28):2765-75.
doi: 10.1093/eurheartj/ehab115
Opstal TSJ, Hoogeveen RM, Fiolet ATL, Silvis MJM, The SHK,
Bax WA, et al. Colchicine Attenuates Inflammation Beyond the
Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2
Proteomic Substudy. Circulation. 2020;142(20):1996-8. doi:
1161/circulationaha.120.050560
Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos
N, Filippatos G, Papoutsidakis N, et al. Anti-inflammatory
treatment with colchicine in acute myocardial infarction:
a pilot study. Circulation. 2015;132:1395-403. doi: 10.1161/
circulationaha.115.017611
D’Amario D, Cappetta D, Cappannoli L, Princi G, Migliaro S,
Diana G, et al. Colchicine in ischemic heart disease: the good, the
bad and the ugly. Clin Res Cardiol. 2021;110(10):1531-42. doi:
1007/s00392-021-01828-9
Akodad M, Lattuca B, Nagot N, Georgescu V, Buisson M, Cristol
JP, et al. COLIN trial: Value of colchicine in the treatment of
patients with acute myocardial infarction and inflammatory
response. Arch Cardiovasc Dis. 2017;110(6-7):395-402. doi:
1016/j.acvd.2016.10.004
Hennessy T, Soh L, Bowman M, Kurup R, Schultz C, Patel S, et al.
The Low Dose Colchicine after Myocardial Infarction (LoDoCoMI) study: a pilot randomized placebo controlled trial of colchicine
following acute myocardial infarction. Am Heart J. 2019;215:62-9.
doi: 10.1016/j.ahj.2019.06.003
Vilela EM, Fontes- Carvalho R. Inflammation and ischemic heart
disease: The next therapeutic target? Rev Port Cardiol (Engl Ed)
[Internet]. 2021[cited 2022 Nov 27]; S0870-2551(21)00321-8.
Available from: https://www.sciencedirect.com/science/
article/pii/S0870255121003218?via%3Dihub doi: 10.1016/j.
repc.2021.02.011
Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP,
et al. Efficacy and safety of low-dose colchicine after myocardial
infarction. N Engl J Med. 2019;381(26):2497-2505. doi: 10.1056/
nejmoa1912388
Butt AK, Cave B, Maturana M, Towers WF, Khouzam RN.
The Role of Colchicine in Coronary Artery Disease. Curr Probl
Cardiol [Internet]. 2021[cited 2022 Nov 30];46(3):100690.
Available from: https://www.sciencedirect.com/science/article/
abs/pii/S0146280620301675?via%3Dihub doi: 10.1016/j.
cpcardiol.2020.100690
Tong DC, Quinn S, Nasis A, Hiew C, Roberts- Thomson P, Adams
H, et al. Colchicine in Patients With Acute Coronary Syndrome:
the Australian COPS Randomized Clinical Trial. Circulation.
;142(20):1890-900. doi: 10.1161/circulationaha.120.050771
Bresson D, Roubille F, Prieur C, Biere L, Ivanes F, Bouleti C,
et al. Colchicine for Left Ventricular Infarct Size Reduction
in Acute Myocardial Infarction: A Phase II, Multicenter,
Randomized, Double- Blinded, Placebo- Controlled Study Protocol
– The COVERT-MI Study. Cardiology. 2021;146(2):151-60. doi:
1159/000512772
Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis
DA, Giotaki SG, et al. Colchicine in Cardiovascular Disease: InDepth Review. Circulation. Circulation. 2022;145(1):61-78. doi:
1161/circulationaha.121.056171
Condello F, Sturla M, Reimers B, Liccardo G, Stefanini GG,
Condorelli G, et al. Association Between Colchicine Treatment
and Clinical Outcomes in Patients with Coronary Artery Disease:
Systematic Review and Meta-analysis. Eur Cardiol [Internet].
[cited 2022 Nov 27];16: e39. Available from: https://www.
ncbi.nlm.nih.gov/pmc/articles/PMC8576482/pdf/ecr-16-e39.pdf
doi: 10.15420/ecr.2021.31
Shah B, Pillinger M, Zhong H, Cronstein B, Xia Y, Lorin JD, et al.
Effects of Acute Colchicine Administration Prior to Percutaneous
Coronary Intervention: COLCHICINE-PCI Randomized Trial.
Circ Cardiovasc Interv [Internet]. 2020[cited 2022 Nov 30];13(4):
e008717. Available from: https://www.ahajournals.org/doi/
epub/10.1161/CIRCINTERVENTIONS.119.008717 doi: 10.1161/
CIRCINTERVENTIONS.119.008717
McKnight AH, Katzenberger DR, Britnell SR. Colchicine in Acute
Coronary Syndrome: A Systematic Review. Ann Pharmacother.
;55(2):187-97. doi: 10.1177/1060028020942144
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Авторське право (c) 2023 В.К. Тащук, Р.А. Бота
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Часопис користується «Типовим шаблоном положення про авторські права».
